TGTX - TG Therapeutics, Inc.
| Previous Close | 8.20 |
| Open | 8.29 |
| Bid | 7.79 x 2200 |
| Ask | 7.80 x 800 |
| Day's Range | 7.74 - 8.38 |
| 52 Week Range | 3.32 - 9.38 |
| Volume | 1,180,348 |
| Avg. Volume | 1,337,818 |
| Market Cap | 773.094M |
| Beta (3Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.80 |
- Thomson Reuters StreetEvents
Edited Transcript of TGTX earnings conference call or presentation 12-Nov-19 1:30pm GMT
Q3 2019 TG Therapeutics Inc Earnings Call
- GlobeNewswire
TG Therapeutics to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
NEW YORK, Nov. 12, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company.
- GlobeNewswire
TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update
NEW YORK, Nov. 08, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday, November 12, 2019 at 8:30 AM ET to discuss.
- GlobeNewswire
TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
100% overall response rate (ORR) in relapsed/refractory CLL patients (n=9) treated with U2 (umbralisib + ublituximab) plus venetoclax, with all patients at 12 months achieving.
- Insider Monkey
TG Therapeutics Inc (TGTX): Hedge Funds In Wait-and-See Mode
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- TheStreet.com
2 Small Biotech Stocks Spurt Ahead on Positive Developments
The biotech sector has not been nearly as strong and is still off around 10% from the highs hit earlier in the year, as seen in the SPDR S&P Biotech ETF . TG Therapeutics should file another NDA for the treatment of Chronic Lymphocytic Leukemia, or CLL, in combination with its other late-stage compound TG-1101 sometime in the first half of 2020.
- GlobeNewswire
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company’s novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company’s prespecified ORR target of 40-50%.
- GlobeNewswire
TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as Compared to Ibrutinib Monotherapy
TG Therapeutics, Inc. (TGTX) today announced that final long-term results from the Phase 3 GENUINE study demonstrated that ublituximab in combination with ibrutinib improved progression-free survival (PFS), as determined by Independent Review Committee (IRC). The GENUINE Phase 3 study evaluated ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, compared to ibrutinib monotherapy in patients with relapsed/refractory high-risk chronic lymphocytic leukemia (CLL).
- Simply Wall St.
Is There An Opportunity With TG Therapeutics, Inc.'s (NASDAQ:TGTX) 30% Undervaluation?
In this article we are going to estimate the intrinsic value of TG Therapeutics, Inc. (NASDAQ:TGTX) by taking the...
- GlobeNewswire
TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
NEW YORK, Oct. 02, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood
TG Therapeutics, Inc. (TGTX) today announced the publication of results from the multicenter first-in-human Phase I/Ib combination trial of ublituximab, the Company’s anti-CD20 monoclonal antibody, and umbralisib, the Company’s oral once-daily PI3K delta inhibitor in Blood, the Journal of the American Society of Hematology. Dr. Matthew Lunning, of the Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center and lead enroller on this trial stated, “I have been involved in the development of umbralisib and ublituximab since 2014, and at our institution we have treated over 60 patients on clinical trials with umbralisib and ublituximab (U2) and/or in combination with other agents.
- GlobeNewswire
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
TG Therapeutics, Inc. (TGTX), today announced that data from two Phase 1/2 trials were presented at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL), currently being held in Edinburgh, Scotland.
- GlobeNewswire
TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
NEW YORK, Sept. 20, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- Simply Wall St.
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Benzinga
The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
- GlobeNewswire
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
TG Therapeutics, Inc. (TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are pleased to present the first look at the study design and patient demographics data from our Phase 3 ULTIMATE program.
- GlobeNewswire
TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS
TG Therapeutics, Inc. (TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been accepted for presentation at the upcoming 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held September 11 – 13, 2019 in Stockholm, Sweden. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at www.ectrims-congress.eu.
- GlobeNewswire
TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD
NEW YORK, Aug. 26, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is.
- Thomson Reuters StreetEvents
Edited Transcript of TGTX earnings conference call or presentation 9-Aug-19 12:30pm GMT
Q2 2019 TG Therapeutics Inc Earnings Call
- Benzinga
Large Option Trader Sells TG Therapeutics Calls After Big Run
On Monday morning, Benzinga Pro subscribers received an option alert due to an unusually large TG Therapeutics trade. Due to the relatively complex nature of the options market, options traders are generally considered to be more sophisticated than the average stock trader. In addition, large options traders are often professional, wealthy individuals or institutions, either of which could have unique insight or information about a company.
- Simply Wall St.
What Kind Of Shareholder Owns Most TG Therapeutics, Inc. (NASDAQ:TGTX) Stock?
A look at the shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX) can tell us which group is most powerful. Generally...
Motley FoolTG Therapeutics Inc (TGTX) Q2 2019 Earnings Call Transcript
TGTX earnings call for the period ending June 30, 2019.
- GlobeNewswire
TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
NEW YORK, Aug. 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company.
- GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results and Business Update
NEW YORK, Aug. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, August 9, 2019 at 8:30 AM ET to discuss results.
